Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

EGFR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche gets license for EGFR lung cancer assay

November 25, 2010 - 12:00am

Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.

Science and Environment

AstraZeneca's gefitinib gets FDA approval

November 4, 2010 - 12:00am

Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive...

Science and Environment